

CORPORATE INFORMATION

BOARD OF DIRECTORS

Munir A. Shaikh (Chairman)

Arshad Saeed Husain (Chief Executive Officer)

Kamran Y. Mirza

Ehsan Ali Malik

Sved Anis Ahmed (Chief Financial Officer)

Atif Aslam Bajwa

Shamim Ahmad Khan

AUDIT COMMITTEE

Ehsan Ali Malik (Chairman)

Shamim Ahmad Khan

Kamran Y. Mirza

Abdul Wahab Godil (Acting Chief Internal

Auditor - by invitation)

Syed Anis Ahmed (CFO by invitation)

HUMAN RESOURSE AND REMUNERATION COMMITTEE

Munir A. Shaikh (Chairman)

Atif Aslam Bajwa

Arshad Saeed Husain

Shamim Ahmad Khan

SHARE TRANSFER COMMITTEE

Arshad Saeed Husain (Chairman)

Syed Anis Ahmed

Kamran Y. Mirza

BANKING COMMITTEE

Atif Aslam Bajwa (Chairman)

Arshad Saeed Husain

Syed Anis Ahmed

CHIEF FINANCIAL OFFICER

Syed Anis Ahmed

COMPANY SECRETARY

Malik Saadatullah

AUDITORS

Ernst & Young Ford Rhodes

Sidat Hyder & Company

(a member firm of Ernst & Young)

Chartered Accountants

LEGAL ADVISORS

Orr, Dignam & Co.

Surridge & Beecheno

SHARE REGISTRAR

FAMCO Associates (Pvt) Limited 8-F, Next to Hotel Faran, Nursery Block 6

P.E.C.H.S, Shahrah-e-Faisal

Karachi

BANKERS

Faysal Bank Limited

Ciitibank N.A.

Deutsche Bank AG

MCB Bank Limited

National Bank of Pakistan

Standard Chartered Bank (Pakistan) Limited The Bank of Tokyo-Mitsubishi UFJ Limited

Barclays Bank PLC

REGISTERED OFFICE

Opposite Radio Pakistan

Transmission Centre,

Hyderabad Road, Landhi,

P.O. Box 7229, Karachi Pakistan.

CITY OFFICE

8th Floor, Faysal House,

St-02, Shahrah-e-Faisal, Karachi Pakistan.

WEBSITE

www.abbott.com.pk

SENIOR MANAGEMENT TEAM

Arshad Saeed Husain

(Chief Executive Officer)

Syed Anis Ahmed

(Chief Financial Officer)

Anis A. Shah

(Director Plant Operations)

Asim Shafiq

(General Manager, Abbott Nutrition

International Pakistan)

Habib Ahmed

(Country Manager, Abbott Diagnostics

Division Pakistan)

Dr. Sheikh Adnan Lateef

(Head of Abbott Diabetes Care Pakistan)

Dr. Farrukh Hafeez

(Director Quality Assurance)

Dr. Sarmad Maqbool

(Director Marketing & Strategy)

Seema Khan

(Director Regulatory Affairs)

Dr. Raeef Ahmed

(Director Medical Affairs)

Dr. Suleman Alvi

(Director Business Development)

Rana A. Latif

(Director Manufacturing)

Zahid Hussain

(Director Materials Management)

DIRECTORS' REPORT

The Directors have pleasure in presenting their Report with the accounts of the Company for the first quarter ended March 31, 2015.

FINANCIAL RESULTS

Sales for the quarter were 4% below same quarter last year. Pharmaceutical sales decline of 11% was partially offset by Nutrition sales growth of 29% for the quarter.

Pharma market was sluggish owing to implementation of the new drug policy issued on 5th March 2015 by the government which mandated a rollback in drug prices to October 2013 levels. The Industry has obtained a Stay Order from the Sindh High Court on price rollback.

Gross Profit to sales ratio decreased from 39% to 36% compared to same quarter last year owing to inflation. As a result of cost control, selling and distribution expenses increased by only 3%. Other charges decreased mainly due to decrease in provision for Workers Profit Participation Fund and Workers Welfare Fund in line with profit. Profit after tax was 13% of sales in the current quarter as compared to 14% same quarter last year.

FUTURE OUTLOOK

Despite improvement in the macroeconomic indicators, Pharma industry continues to face pricing and regulatory challenges.

KARACHI: April 24th, 2015

Munir A Shaikh Chairman

1

CONDENSED INTERIM BALANCE SHEET

As At March 31, 2015

AS AL March 31, 2013			
	Notes	UNAUDITED MARCH 31, 2015	AUDITED DECEMBER 31, 2014
Non-Current Assets	Note	(кире	es '000)
Non-Current Assets			
Fixed Assets			1
Property, plant and equipmentIntangible asset	3	3,406,985 20,090 3,427,075	3,359,092 24,395 3,383,487
Long-term loans and advances Long-term deposits Long-term prepayments		45,773 7,546 9,236	46,204 7,605 9,171
Total Non-Current Assets		62,555 3,489,630	62,980 3,446,467
Current Assets			, ,
Stores and spares Stock-in-trade Trade debts Loans and advances Trade deposits and short-term prepayments Accrued profit Other receivables Taxation recoverable Cash and bank balances Current Liabilities Trade and other payables Dividends Net Current Assets Total Assets Less Current Liabilities Non-Current Liability		212,190 3,347,083 429,146 130,060 197,342 10,633 99,338 87,902 6,795,061 11,308,755 3,146,458 469,921 3,616,379 7,692,376 11,182,006	120,158 2,823,007 482,771 81,259 177,948 17,351 192,610 42,643 6,381,381 10,319,128 2,670,042 - 2,670,042 7,649,086 11,095,553
Deferred taxation		206,381	223,953
Contingencies and Commitments NET ASSETS	4	10,975,625	10,871,600
FINANCED BY: Share Capital and Reserves Authorised capital 200,000,000 ordinary shares of Rs.10 each		2,000,000	2,000,000
Issued, subscribed and paid-up capital Reserves - capital - revenue	5	979,003 350,916 9,645,706	979,003 339,481 9,553,116
SHAREHOLDERS' EQUITY		10,975,625	10,871,600
The annexed notes I to 0 form an integral next of this	1 1		1: 6 .:

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

CONDENSED INTERIM PROFIT AND LOSS ACCOUNT (UNAUDITED)

For The Three Months Ended March 31, 2015

	Jan - Mar 2015	Jan - Mar 2014
	(Rupee	s '000)
Sales - net		
Domestic	4,111,890	4,304,375
Export	154,835	144,174
	4,266,725	4,448,549
Cost of goods sold	2,751,165	2,735,363
Gross profit	1,515,560	1,713,186
Selling and distribution expenses	703,444	680,245
Administrative expenses	88,976	97,042
	723,140	935,899
Other income	124,383	146,373
Other operating charges	73,273	84,763
	774,250	997,509
Finance cost	898	754
Profit before taxation	773,352	996,755
Taxation		
- current	228,413	365,423
- deferred	(17,572)	1,377
	210,841	366,800
Profit for the period	562,511	629,955
	(Rupee	s '000)
Earnings per share - basic / diluted	5.75	6.43

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)

For The Three Months Ended March 31, 2015

	Jan - Mar 2015	Jan - Mar 2014	
-	(Rupees '000)		
Profit for the period	562,511	629,955	
Other comprehensive income	-	-	
Total comprehensive income for the period	562,511	629,955	

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

CONDENSED INTERIM CASH FLOW STATEMENT (UNAUDITED)

For The Three Months Ended March 31, 2015

		Jan - Mar	Jan - Mar
		2015	2014
	Note _	(Rupees	'000)
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	6	717,186	983,860
Income taxes paid		(273,672)	(261,317)
Long-term loans and advances - net		431	(9,194)
Long-term deposits - net		59	59
Long-term prepayments - net		(65)	(845)
Net cash inflow from operating activities	_	443,939	712,563
Fixed capital expenditure Sale proceeds from disposal of fixed asssets Interest income		(167,953) 13,721 125,186	(197,678) 13,822 91,316
Net cash outflow from investing activities		(29,046)	(92,540)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance cost paid		(898)	(754)
Dividend paid		(315)	(60)
Net cash outflow from financing activities	_	(1,213)	(814)
Net increase in cash and cash equivalents		413,680	619,209
Cash and cash equivalents at the beginning of the period	_	6,381,381	3,897,051
Cash and cash equivalents at the end of the period	_	6,795,061	4,516,260
	_		

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For The Three Months Ended March 31, 2015

		Reserves					
	Share	Capital Reserves		Revenue	Reserves		Total
	Capital	Reserve arising on Merger	Other	General Reserve	Un-ap- propriated Profit	Total	Equity
			((Rupees '000)			
Balance as at December 31, 2013 Total comprehensive income for the three months ended March 31, 2014	979,003	46,097	253,933	5,338,422	2,129,810	7,768,262	8,747,265
Profit for the period	-	-	-	-	629,955	629,955	629,955
Other comprehensive income for the period, net of tax	-	-	-	-	-	-	_
Total comprehensive income for the period	-	-	-	-	629,955	629,955	629,955
Transactions with owners, recorded directly in equity Final dividend for the year ended December 31, 2013 @ Rs. 4 per share declared subsequent to the year end	_	_	_	_	(391,601)	(391,601)	(391,601)
Capital contribution from Abbott International LLC, USA	_	-	12,457	-	-	12,457	12,457
Balance as at March 31, 2014	979,003	46,097	266,390	5,338,422	2,368,164	8,019,073	8,998,076
Balance as at December 31, 2014	979,003	46,097	293,384	5,338,422	4,214,694	9,892,597	10,871,600
Total comprehensive income for the three months ended March 31, 2015							
Profit for the period	-	-	-	-	562,511	562,511	562,511
Other comprehensive income for the period, net of tax	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	562,511	562,511	562,511
Transactions with owners, recorded directly in equity Final dividend for the year ended December 31.							
2014 @ Rs. 4.8 per share declared subsequent to the year end	-	-	-	-	(469,921)	(469,921)	(469,921)
Capital contribution from Abbott International LLC, USA	-	-	11,435	-	-	11,435	11,435
Balance as at March 31, 2015	979,003	46,097	304,819	5,338,422	4,307,284	9,996,622	10,975,625

The annexed notes 1 to 9 form an integral part of this condensed interim financial information.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

For The Three Months Ended March 31, 2015

1. THE COMPANY AND ITS OPERATIONS

Abbott Laboratories (Pakistan) Limited (The Company) is a public limited Company incorporated in Pakistan on July 02, 1948, and its shares are quoted on the Karachi, Lahore and Islamabad stock exchanges. The address of its registered office is opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of research based pharmaceutical, nutritional, diagnostic, diabetic care, molecular devices, hospital and consumer products.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

Statement of compliance

This condensed interim financial information has been prepared in accordance with the requirements of the International Accounting Standard 34 – "Interim Financial Reporting" and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed. This condensed interim financial information does not include all of the information and disclosures required for annual financial statements, and should be read in conjunction with the financial statements of the Company as at and for the year ended December 31, 2014. This condensed interim financial information is unaudited.

2.2 Accounting policies

The accounting policies and the methods of computation adopted in the preparation of this condensed interim financial information are the same as those applied in the preparation of the financial statements for the year ended December 31, 2014.

2.3 Accounting estimates and judgments.

The preparation of condensed interim financial information in conformity with approved accounting standards, as applicable in Pakistan requires the management to make estimates, assumptions and use judgments that affect the application of policies and the reported amount of assets and liabilities and income and expenses.

Estimates and judgments made by management in the preparation of this condensed interim financial information are the same as those that were applied to the audited annual financial statements of the Company as at and for the year ended December 31, 2014.

For The Three Months Ended March 31, 2015

		UNAUDITED Jan - Mar 2015	UNAUDITED Jan - Mar 2014 es '000)
3.	PROPERTY, PLANT AND EQUIPMENT [COST OF ADDITIONS / (DELETIONS)]	(кирес	3 000)
	Buildings on freehold land	7,260	-
	Plant and machinery	54,811	-
	Office equipment	5,460	-
	Vehicles	32,223 (24,262)	17,143 (21,719)
	Computers	592	2,145
	Demonstration equipments	42,421	83,831 (20,966)
	Capital work in progress (CWIP) - net	25,186	94,559
	Total additions	167,953	197,678
	Total (deletions)	(24,262)	(42,685)

4. CONTINGENCIES AND COMMITMENTS

4.1 Contingencies

4.1.1 The Company has given bank guarantees of Rs. 146.943 million (December 31, 2014: Rs 135.054 million) to the Customs Department, a utility company and other institutions against tenders.

4.2 Commitments

- 4.2.1 Commitments for capital expenditure as at March 31, 2015 aggregated to Rs. 437.103 million (December 31, 2014: Rs. 353.850 million).
- 4.2.2 The Company has obtained short term financing facilities from various commercial banks amounting to Rs. 1,020 million (December 31, 2014: Rs. 1,020 million). These facilities can be utilized for letters of credit, guarantees and running finance / short term loans. However, the running finance / short term loan utilization cannot exceed Rs. 250 million (December 31, 2014: Rs. 250 million). The running finance / short term loan carries markup at rates ranging from KIBOR plus 1% to KIBOR plus 2% (December 31, 2014: KIBOR plus 1% to KIBOR plus 2%) and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not borrowed any amount against running finance / short term loan facilities at the balance sheet date. Commitments in respect of letters of credit as at balance sheet date aggregated to Rs. 590.068 million (December 31, 2014: Rs. 447.727 million).

5. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

As at March 31, 2015, Abbott Asia Investments Limited, UK held 76,259,454 (December 31, 2014: 76,259,454) shares. The ultimate holding company is Abbott International LLC, USA.

For The Three Months Ended March 31, 2015

			UNAUDITED Jan - Mar	UNAUDITED Jan - Mar
		Note	2015 (Rupee	2014 es '000)
6.	CASH GENERATED FROM OPERATIONS			
	Profit before taxation		773,352	996,755
	Adjustment for:			
	Depreciation		108,762	102,440
	Amortisation on intangible asset		4,305	4,305
	Gain on disposal of fixed assets		(2,422)	(3,636)
	Income on investments and deposits		(118,468)	(91,112)
	Expense recognised in profit or loss in respect			
	of equity-settled share-based payments		11,435	12,457
	Finance cost		898	754
	Working capital changes	6.1	(60,676)	(38,103)
			717,186	983,860
6.1	Working capital changes			
	(Increase) / decrease in current assets net of prov	ision		
	Stores and spares		(92,032)	12,413
	Stock-in-trade		(524,076)	(312,636)
	Trade debts		53,625	112,452
	Loans and advances		(48,801)	(4,207)
	Trade deposits and short-term prepayments		(19,394)	(46,695)
	Other receivables		93,272	2,460
			(537,406)	(236,213)
	Increase in current liabilities			
	Trade and other payables - net		476,730	198,110
			(60,676)	(38,103)

For The Three Months Ended March 31, 2015

7. TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise other related parties, employee retirement benefit plans, directors and key management personnel. Transactions with related parties essentially entail sale and purchase of goods and services and expenses charged between these parties. Transactions with related parties are as follows:

	UNAUDITED Jan - Mar 2015 (Rupee	UNAUDITED Jan - Mar 2014 es '000)
Other related parties		
Sale of goods Purchase of materials Technical service fee	29,553 1,009,575 24,072	31,741 963,873 31,554
Reimbursements from a related party on account of:		
Selling and distribution expenses Administrative expenses	19,597 1,898	17,344 2,617
Interest income earned	8,091	7,192
Charge in respect of staff retirement benefit plans:		
Pension fund Provident fund	35,876 17,453	31,648 15,516
Key management personnel		
Short-term employee benefits Post-employment benefits	55,555 6,192	49,533 5,052

8. SEGMENT ANALYSIS

8.1 Segment wise operating results for the first quarter:

	UNAUDITED			UNAUDITED				
	Jan - Mar 2015				Jan - Mar			
						20)14	
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
				(Rupees '0	00)			
Sales Less:	3,095,312	899,646	436,352	4,431,310	3,451,062	700,783	420,069	4,571,914
Sales return and discount Sales tax and	47,119	803	15,434	63,356	25,098	-	2,628	27,726
excise duty	_	82,203	19,026	101,229		65,421	30,218	95,639
Sales - net Cost of goods sold	3,048,193 2,008,356	816,640 499,685	401,892 243,124	4,266,725 2,751,165	3,425,964 2,042,061	635,362 432,230	387,223 261,072	4,448,549 2,735,363
Gross profit Selling and distribution	1,039,837	316,955	158,768	1,515,560	1,383,903	203,132	126,151	1,713,186
expenses	491,297	119,055	93,092	703,444	492,275	111,383	76,587	680,245
Administrative expenses	75,142	9,003	4,831	88,976	82,704	10,560	3,778	97,042
Segment result	473,398	188,897	60,845	723,140	808,924	81,189	45,786	935,899

UNAUDITED UNAUDITED

4,266,725

4,448,549

SELECTED NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION (UNAUDITED)

For The Three Months Ended March 31, 2015

8.2 Reconciliation of segment results with profit before taxation

	Jan - Mar 2015 (Rupees	Jan - Mar 2014 s '000)
Total segment results Other income Other operating charges Finance cost	723,140 124,383 73,273 898	935,899 146,373 84,763 754
Profit before taxation	773,352	996,755
Geographical information		
Sales to external customers, net of retun, discounts, sales tax and excise duty		
Pakistan Afghanistan Srilanka Netherland Switzerland	4,111,890 123,714 1,568 8,242 21,311	4,304,375 112,433 6,321 25,420

8.4 Segment Assets

8.3

	UNAUDITED			AUDITED				
	March 31, 2015			December 31, 2014				
	Pharmaceutical	Nutritional	Others	Total	Pharmaceutical	Nutritional	Others	Total
	(Rupees '000)							
Segment assets employed	5,714,463	613,329	1,136,756	7,464,548	5,332,042	402,983	1,138,869	6,873,894
Unallocated corporate assets				7,304,728				6,891,701
Total reported assets				14,769,276				13,765,595

9. Date of Authorisation

This condensed interim financial information was authorised for issue on April 24, 2015 by the Board of Directors of the Company.

ARSHAD SAEED HUSAIN CHIEF EXECUTIVE

NOTES

ABBOTT LABORATORIES (PAKISTAN) LIMITED

Registered Office

Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, P.O. Box 7229, Karachi Phone:111-ABBOTT (111-222-688) Fax: (92-21) 35001903

City Office

8th Floor, Faysal House, St-02, Shahrah-e-Faisal, Karachi Phone: (92-21) 32799018, 32799019 Fax: (92-21) 32800244

URL: www.abbott.com.pk

